NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global ...

The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

Fifty-year-old Tapestry says it provides syringe access, overdose prevention, HIV and hepatitis C testing, and health care across Western Massachusetts.

The World Health Organization (WHO) has released the Integrated drug resistance action framework for HIV, hepatitis B and C ...

WHO releases new framework to tackle drug resistance to HIV, hepatitis B and C, and STIs: Geneva Thursday, November 27, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) h ...

The World Health Organization (WHO) has released the Integrated drug resistance action framework for HIV, hepatitis B and C and sexually transmitted infections, 2026–2030, a landmark roadmap ...

From pioneering World Hepatitis Day to raising alarms on the surge of NAFLD and other liver diseases, abuse of diagnostic ...

The initiative, funded by a $12 million grant from the National Institute on Drug Abuse, will evaluate how people with ...

BOSTON - Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) announced Friday that new modeling data predicts its combination regimen of bemnifosbuvir and ruzasvir could achieve near-complete inhibition of ...

The Hepatitis B and C Therapeutics Market has entered a renewed growth cycle in 2024, led by innovative antiviral regimens, ...

Researchers from the University of Vermont and several other institutions this spring will launch a multi-year study focused ...

From pioneering World Hepatitis Day to raising alarms on the surge of NAFLD and other liver diseases, abuse of diagnostic ...